?Finerenone Intermediate (CAS 1050477-27-4)?
Google Keywords: Finerenone Intermediate, CAS 1050477-27-4, Nonsteroidal MRA, Chronic Kidney Disease Treatment, Pharmaceutical Intermediates

?? ?Product Overview?

?Finerenone Intermediate? (CAS 1050477-27-4) is a critical building block in synthesizing ?Finerenone?, a nonsteroidal mineralocorticoid receptor antagonist (MRA) approved for treating chronic kidney disease (CKD) and type 2 diabetes. This high-purity intermediate ensures reliable and scalable production of APIs for cardiovascular and renal therapies.

• ?Primary Function?: Enables precise synthesis of Finerenone with controlled impurity profiles.

• ?Applications?: CKD/diabetes drug manufacturing, clinical trials, and generic API development.

? ?Key Advantages?

?? ?Ultra-High Purity? | ≥99% (HPLC/GC verified) | Low residual solvents (<50 ppm).
?? ?Scalability? | Optimized for batch-to-batch consistency in large-scale production.
?? ?Regulatory Compliance? | Meets ICH Q11 and GMP guidelines for intermediates.

?? ?Applications?

1. ?Cardiovascular Drugs?: Core component in Finerenone API production for CKD and heart failure therapies.

2. ?Clinical Research?: Supports formulation studies and regulatory submissions.

3. ?Generic Drug Development?: Key material for post-patent API synthesis.

?? ?Quality Assurance?

• ?Testing Methods?: HPLC, GC, NMR, and LC-MS for identity, purity, and stability.

• ?Standards?: Complies with USP/EP specifications and ISO 9001:2015 quality systems.

?? ?Market Trends?

The global CKD treatment market is projected to reach ?$22.5 billion by 2030? (CAGR 6.8%), driven by rising diabetes prevalence and demand for nonsteroidal MRAs like Finerenone. This intermediate is pivotal in addressing unmet medical needs in renal and metabolic disorders.

Accelerate your drug development with Finerenone Intermediate – precision, compliance, and scalability for life-saving therapies.